Perspective Therapeutics Inc (CATX)
2.645
-0.06
(-2.40%)
USD |
NYAM |
Oct 09, 16:00
2.645
0.00 (0.00%)
After-Hours: 18:21
Perspective Therapeutics Enterprise Value : 76.26M for Oct. 8, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 08, 2026 | 76.26M |
| October 07, 2026 | 47.74M |
| October 06, 2026 | 36.33M |
| October 05, 2026 | 60.29M |
| October 02, 2026 | 81.96M |
| October 01, 2026 | 77.40M |
| September 30, 2026 | 80.82M |
| September 29, 2026 | 65.99M |
| September 28, 2026 | 52.30M |
| September 25, 2026 | 54.58M |
| September 24, 2026 | 52.30M |
| September 23, 2026 | 65.99M |
| September 22, 2026 | 104.78M |
| September 21, 2026 | 105.92M |
| September 18, 2026 | 95.66M |
| September 17, 2026 | 95.66M |
| September 16, 2026 | 75.12M |
| September 15, 2026 | 78.54M |
| September 14, 2026 | 100.22M |
| September 11, 2026 | 87.67M |
| September 10, 2026 | 83.11M |
| September 09, 2026 | 108.20M |
| September 08, 2026 | 123.04M |
| September 04, 2026 | 124.18M |
| September 03, 2026 | 123.04M |
| Date | Value |
|---|---|
| September 02, 2026 | 120.75M |
| September 01, 2026 | 120.75M |
| August 31, 2026 | 127.60M |
| August 28, 2026 | 121.89M |
| August 27, 2026 | 129.88M |
| August 26, 2026 | 127.60M |
| August 25, 2026 | 142.43M |
| August 24, 2026 | 131.02M |
| August 21, 2026 | 143.57M |
| August 20, 2026 | 133.30M |
| August 19, 2026 | 164.11M |
| August 18, 2026 | 133.30M |
| August 17, 2026 | 134.44M |
| August 14, 2026 | 132.16M |
| August 13, 2026 | 120.75M |
| August 12, 2026 | 139.01M |
| August 11, 2026 | 129.88M |
| August 10, 2026 | 109.35M |
| August 07, 2026 | 109.35M |
| August 06, 2026 | 105.92M |
| August 05, 2026 | 102.50M |
| August 04, 2026 | 109.35M |
| August 03, 2026 | 110.49M |
| July 31, 2026 | 99.08M |
| July 30, 2026 | 108.20M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Biogen, Inc. | 39.33B |
| Rigel Pharmaceuticals, Inc. | 853.44M |
| Enanta Pharmaceuticals, Inc. | 344.89M |
| Insight Molecular Diagnostics, Inc. | 91.14M |
| BridgeBio Pharma, Inc. | 15.39B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -26.98M |
| Revenue (Quarterly) | 0.081M |
| Total Expenses (Quarterly) | 27.06M |
| EPS Diluted (Quarterly) | -0.222 |
| Gross Profit Margin (Quarterly) | -1.31K% |
| Profit Margin (Quarterly) | -33.31K% |
| Earnings Yield | -50.23% |
| Normalized Earnings Yield | -46.67 |